Brief: AFT Pharmaceuticals Says FY24 Result Will Be Significantly Influenced By US Licensing Income
08/01/2024 19:46
Jan 9 (Reuters) - AFT Pharmaceuticals AFT.NZ :
* FY24 RESULT WILL BE SIGNIFICANTLY INFLUENCED BY TIMING OF
LUMPY
LICENSING INCOME IN USA
* IF SUCCESFULLY EXECUTE MAXIGESIC IV IN USA WITHIN FY24,
WILL
RESULT IN AROUND NZ$6 MILLION BEING BOOKED TO FY24 PROFIT
Further company coverage: AFT.NZ
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AFT Pharmaceuticals
See all newsNZ's AFT Pharma eyes highest weekly gain in over 2 months after results
Brief: AFT Pharmaceuticals Reports Double Digit Revenue Growth In 1H FY27
NZ's AFT Pharmaceuticals gains most in over 2 weeks on strong half-year results
Brief: AFT Pharmaceuticals Enters Exclusive Development, License And Supply Agreement With Mikasaseiyaku
NZ's AFT Pharma rises to near 1-month high on Japan licensing deal for Maxigesic IV